Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CNR2 | P34972 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412847 | 1.00 | POLB (0.59) | POLBALDH1A1CNR2MEN1CYP1A2 | |
| SCHEMBL10432164 | 1.00 | POLB (0.59) | POLBALDH1A1CNR2MEN1CYP1A2 | |
| Alanine SCHEMBL1679645 | 0.94 | POLB (0.54) | POLBALDH1A1CNR2MEN1CYP1A2 | |
| SCHEMBL7361586 | 0.91 | ALDH1A1 (0.67) | POLBALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL31186640 | 0.89 | ALDH1A1 (0.56) | POLBALDH1A1CNR2MEN1CYP1A2 | |
| SCHEMBL9832132 | 0.89 | POLB (0.52) | POLBALDH1A1CNR2MEN1CYP1A2 | |
| SCHEMBL9832138 | 0.89 | POLB (0.52) | POLBALDH1A1CNR2MEN1CYP1A2 | |
| SCHEMBL16114948 | 0.88 | POLB (0.58) | POLBALDH1A1CNR2MEN1CYP1A2 | |
| SCHEMBL10417010 | 0.88 | POLB (0.58) | POLBALDH1A1CNR2MEN1CYP1A2 | |
| SCHEMBL6138095 | 0.88 | POLB (0.58) | POLBALDH1A1CNR2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230064307-A1 | Pharmaceutical composition to destabilize abnormal methylation enzymes and use thereof | LIAU MING C (US) | 2023-03-02 | — | — | US | claimed |
| US-20220221433-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. | 2022-07-14 | — | — | US | claimed |
| EP-3977112-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | Metabolon Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| CN-113892029-A | Mass spectrometry method for detecting metabolites | 梅塔博隆股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| WO-2020242744-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. (US) | 2020-12-03 | — | — | WO | claimed |
| EP-0951464-B1 | N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2005-05-11 | — | — | EP | claimed |
| EP-1494700-A2 | CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS | Cytovia, Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2004002401-A2 | CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS | CYTOVIA, INC. (US) | 2004-01-08 | — | — | WO | claimed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | claimed |
| JP-5201945-A | — | — | None | — | — | JP | disclosed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230064307-A1 | Pharmaceutical composition to destabilize abnormal methylation enzymes and use thereof | LIAU MING C (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220221433-A1 | MASS SPECTROMETRY ASSAY METHODS FOR DETECTION OF METABOLITES | METABOLON, INC. | 2022-07-14 | — | — | US | disclosed |
| CN-1068333-A | Has hydrazine analog derivative of pharmacologically active and preparation method thereof | CIBA GEIGY AG (CH) | 1993-01-27 | — | — | CN | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| US-4638086-A | BENZOIC OR PHENYLACETIC ACID OR DERIVATIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | POLB 684/4885ALDH1A1 4592/4885CNR2 4559/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | POLB 684/4885ALDH1A1 4592/4885CNR2 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.